On Aug 25, 2021 Cardior Pharmaceuticals closed a Series B round and raised €64,000,000 from BioMedPartners, Bristol Myers Squibb, coparion, Fund+, Hadean Ventures, High-Tech Grunderfonds, INKEF Capital, Life Sciences Partners, Sunstone Partners, featuring lead investors INKEF Capital.

About the company: Cardior Pharmaceuticals is located in Germany, Europe. The company is a “clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases”

Company website: cardior.de